Dupilumab Safe, Effective Over 5 Years in Moderate-Severe AD
TOPLINE:Over 5 years, dupilumab demonstrated acceptable safety and sustained efficacy, with significant improvements in the signs and symptoms of AD, ...
Read moreDetails
Tag: Dupilumab
Dupilumab Effective in PPI-Refractory Pediatric EoE
Good news for younger children suffering from the uncommon but debilitating gastrointestinal condition eosinophilic esophagitis (EoE). A randomized placebo-controlled study ...
Read moreDetails
Dupilumab Improves Outcomes in COPD With Type 2 Inflammation
Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 ...
Read moreDetails
Dupilumab for EoE: How Is it Improving Treatment?
The US Food and Drug Administration approvals of dupilumab (Dupixent, Regeneron/Sanofi) for adults and children with eosinophilic esophagitis (EoE) affirmed ...
Read moreDetails
The Earth News is an independent English-language daily published Website from all around the World News
